Apolipoprotein AI, Immunogen Grade
Produktgrößen
0.5 mg
£202,50
16-16-120101-IMM-0.5MG
1 mg
£337,50
16-16-120101-IMM-1MG
Über dieses Produkt
- SKU:
- 16-16-120101-IMM
- Zusätzliche Namen:
- ApoAI|In Vitro Diagnostic, Cardiovascular Research, ALS, Diabetes, Cell Based Assays
- Anwendung:
- Cell-based/Functional Assay
- Buffer:
- Frozen in 10 mM NH4HCO3, pH 7.4
- CE/IVD:
- RUO
- Weitere Details:
- Apolipoprotein AI (Apo AI), constituting 75% of HDL-associated apolipoproteins, is a critical for reverse cholesterol transport (RCT), mediating cholesterol efflux from peripheral tissues to the liver. As the primary structural component of HDL, Apo AI stabilizes discoidal HDL particles, activates lecithin-cholesterol acyltransferase (LCAT) to esterify cholesterol, and facilitates HDL maturatioN. Its anti-inflammatory properties include blocking T-cell-monocyte interactions, reducing TNF-A Alpha and IL-1B Beta production, and neutralizing oxidized LDL. Normal plasma levels range from 90-130 mg/100 mL, with concentrations inversely correlating with coronary heart disease (CHD) risk. Deficiencies in Apo AI underlie Tangier disease, characterized by near-absent HDL, cholesterol-laden macrophages, and premature atherosclerosis. Mutations like APOA1 p.Leu202Arg cause systemic amyloidosis, leading to cardiac and renal dysfunction. Reduced Apo AI levels also associate with insulin resistance, impaired B Beta-cell function, and diabetes progression. Conversely, Apo AI overexpression enhances macrophage-specific RCT, attenuating atherosclerosis.
- Formulierung:
- Frozen in 10 mM NH4HCO3, pH 7.4
- Molekulargewicht:
- 28,000 Da
- Physischer Zustand:
- Frozen
- Reinheit:
- ≥98%
- Aufreinigung:
- Liquid Chromatography Methods
- Versandbedingungen:
- Dry Ice
- Quelle:
- Source human plasma non-reactive for HBsAG, anti-HCV, anti-HBc, and negative for anti-HIV 1 & 2 by FDA approved tests.
- Typ:
- Proteins, Peptides, Small Molecules & Other Biomolecules: Native